Cryptocurrencies
Moderna Stock Leaps On Positive Data From Late-Stage RSV Vaccine Trial
“We are committed to developing a portfolio of respiratory mRNA vaccines to target the most significant viruses causing respiratory disease, including COVID-19, influenza, and human metapneumovirus,” said CEO Stéphane Bancel. Moderna (MRNA) – Get Free Read more…